Share This Special Issue

Special Issue Editor

Dr. David Drobne

E-Mail Website
Guest Editor

Department of Gastroenterology, University Medical Centre Ljubljana, 1231 Ljubljana, Slovenia
Interests: inflammatory bowel disease; pharmacokinetics; epidemiology; precision medicine

Special Issue Information

Dear Colleagues,

Inflammatory bowel disease burden is increasing worldwide at an accelerated rate and thus represents a tremendous burden for society. Fortunately, IBD is one of most lively IBD research topics in gastroenterology. Furthermore, drug development also followed many of the unmet needs in the field.

The aim of this Special issue will be to report on recent findings in the field of IBD with a special focus on real world evidence on the efficacy of different treatments for IBD. We also welcome epidemiological reports that would help understand the burden and management of IBD worldwide.

Authors can submit research papers, short reports, reviews, systematic reviews, and meta-analyses.

Dr. David Drobne
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

IBD
biologicals
IBD surgery
epidemiology
complications
fistula
mucosal healing
patient-reported outcomes
therapeutic drug monitoring
optimisation of treatment

Published Papers (1 paper)

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

12 pages, 631 KiB

Open AccessArticle

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease

by Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar and Gregor Novak

Medicina 2024, 60(2), 296; https://doi.org/10.3390/medicina60020296 - 09 Feb 2024

Viewed by 832

Abstract

Background and Objectives: The subcutaneous (SC) formulation of vedolizumab has proven to be effective for the maintenance of remission after intravenous induction. Little is known about the efficacy of switching from intravenous maintenance treatment to SC. We aimed to assess the real-world efficacy of switching to SC treatment and to assess the impact of a baseline treatment regimen. Materials and Methods: In this observational cohort study, adult patients with inflammatory bowel disease who were switched to SC vedolizumab maintenance treatment were enrolled. Patients after intravenous induction and patients who switched from intravenous maintenance treatment (every 8 weeks or every 4 weeks) were included. The SC vedolizumab dosing was 108 mg every 2 weeks, regardless of the previous regimen. The clinical, biochemical, and endoscopic disease activity parameters and vedolizumab serum concentrations at the time of the switch and at the follow-up were assessed. Results: In total, 135 patients (38% Crohn’s disease, 62% ulcerative colitis) were switched to SC vedolizumab treatment. The median time to the first follow-up (FU) was 14.5 weeks (IQR 12–26), and the median time to the second FU was 40 weeks (IQR 36–52). Nine patients (7%) discontinued SC vedolizumab treatment, with two-thirds of them discontinuing due to active disease. In all dosing regimens, there were no significant changes in the clinical scores and CRP at the baseline and first and second FUs. Clinical and biochemical remission appeared to be maintained irrespective of the previous dosing regimen. Conclusions: The results of this real-world study suggest that the maintenance of clinical and biomarker remission can be achieved in patients who switched from intravenous to SC vedolizumab. The baseline vedolizumab dosing regimen (every 4 weeks versus every 8 weeks) did not have an impact on outcomes. Full article

(This article belongs to the Special Issue New Trends in Crohn’s Disease and Ulcerative Colitis)

► Show Figures

Journal Menu

Journal Browser

New Trends in Crohn’s Disease and Ulcerative Colitis

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI